| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 24.456 | 24.750 | 31.001 | 35.481 | 37.585 | 34.561 | 46.305 | 52.671 | 55.756 | 59.186 |
| Total Income - EUR | 24.456 | 25.285 | 32.035 | 35.482 | 37.585 | 36.032 | 46.881 | 57.690 | 55.756 | 75.211 |
| Total Expenses - EUR | 21.435 | 23.523 | 29.872 | 33.912 | 35.435 | 30.096 | 37.205 | 46.096 | 49.822 | 69.830 |
| Gross Profit/Loss - EUR | 3.021 | 1.761 | 2.164 | 1.570 | 2.150 | 5.936 | 9.676 | 11.594 | 5.934 | 5.381 |
| Net Profit/Loss - EUR | 2.287 | 1.266 | 1.854 | 1.217 | 1.774 | 5.678 | 9.254 | 11.138 | 5.460 | 4.815 |
| Employees | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 |
Check the financial reports for the company - Imodor Natmed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 824 | 328 | 387 | 126 | 0 | 0 | 0 | 0 | 14.625 |
| Current Assets | 7.497 | 6.319 | 6.531 | 7.677 | 9.628 | 14.747 | 24.116 | 31.328 | 31.992 | 14.939 |
| Inventories | 3.488 | 3.108 | 2.722 | 2.537 | 2.492 | 2.956 | 3.559 | 3.121 | 13.061 | 6.048 |
| Receivables | 458 | 276 | 347 | 926 | 937 | 1.076 | 1.085 | 869 | 1.086 | 1.746 |
| Cash | 3.551 | 2.934 | 3.462 | 4.215 | 6.199 | 10.714 | 19.472 | 27.338 | 17.845 | 7.145 |
| Shareholders Funds | 2.419 | 3.661 | 5.453 | 6.570 | 8.217 | 13.739 | 22.688 | 29.628 | 30.603 | 28.691 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 5.078 | 3.482 | 1.406 | 1.494 | 1.538 | 1.008 | 1.428 | 1.700 | 1.389 | 872 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4776 - 4776" | |||||||||
| CAEN Financial Year |
4776
|
|||||||||
Comments - Imodor Natmed Srl